• Users Online: 951
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

   Table of Contents      
REVIEW ARTICLE
Year : 2021  |  Volume : 7  |  Issue : 1  |  Page : 18-22

Stem cell secretome derived from human amniotic fluid affords neuroprotection in an ischemic model


1 Judy Genshaft Honors College, University of South Florida, Tampa, FL 33612, USA
2 Molecular Genetics Unit, CeSI-Met, Chieti, Italy

Date of Submission18-Nov-2020
Date of Decision03-Jan-2021
Date of Acceptance20-Jan-2021
Date of Web Publication30-Mar-2021

Correspondence Address:
Liborio Stuppia
Molecular Genetics Unit, CeSI-Met, Chieti
Italy
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/bc.bc_8_21

Rights and Permissions
  Abstract 


Human amniotic fluid stem cells (hAFSCs) are growing in interest; yet, little is understood about their secretome and neuroprotective actions in different diseases, including stroke. When stem cells are grown in vitro, they release an array of cytokines and growth factors that can stimulate neuroprotective processes. Furthermore, administering secretome rather than cells may be a safer route for patients who are at risk for rejection, promoting innate restorative processes. Current literature implicates that the miRNA contents of such secretome, more specifically exosomes, may regulate the effectiveness of secretome administration. In this review, we explore what factors may promote pro-survival and pro-apoptotic pathways after the administration of hAFSCs-derived secretome in ischemic models.

Keywords: miRNAs, oxygen-glucose deprivation, secretome, stroke


How to cite this article:
Kingsbury C, Stuppia L. Stem cell secretome derived from human amniotic fluid affords neuroprotection in an ischemic model. Brain Circ 2021;7:18-22

How to cite this URL:
Kingsbury C, Stuppia L. Stem cell secretome derived from human amniotic fluid affords neuroprotection in an ischemic model. Brain Circ [serial online] 2021 [cited 2022 Jun 27];7:18-22. Available from: http://www.braincirculation.org/text.asp?2021/7/1/18/312692




  Introduction: Update on Stroke Top


Stroke remains a significant cause of death and chronic disability across the world. The two major subcategories of stroke are ischemic and hemorrhagic. Ischemic stroke results from occlusion of an artery that supplies blood to the brain,[1] while hemorrhagic stroke is caused by a ruptured artery or an unusual vascular design.[2],[3] Recent data have shown that the majority of stroke incidences are ischemic in nature.[4] A disruption in the cerebral blood supply has devastating effects, such as oxidative stress, tissue damage, inflammation, and eventually death of resident neurons.[5],[6] Currently, stroke treatment is limited to tissue plasminogen activator (tPA), which has a narrow therapeutic window.[5],[6],[7] Furthermore, tPA has other limitations such as cerebral ischemia/reperfusion (I/R) injury, which can cause severe disability and even mortality.[8],[9],[10] Due to the unfavorable outcomes of current treatment options like I/R injury, treatments that target secondary inflammation pathways, warrant the need to be investigated.

[TAG:2] In vitro Methods Provide Insight into Molecular Actions[/TAG:2]

In vitro mechanisms are useful in understanding the cellular and molecular actions of pathologies like stroke. Although not complete, in vitro models are critical for the translation of a treatment to a clinical setting. Furthermore, they allow for a lost-cost solution to develop in vivo models, which further improve the clinical translation.

Oxygen and glucose deprivation models (OGD) are an accurate way to simulate cerebral ischemia and cell damage that occur during stroke in vitro.[11],[12],[13] This model is accomplished by placing cells in a glucose-free medium while simultaneously prohibiting oxygen.[13],[14] Further, the OGD model undergoes reperfusion in normal oxygen conditions.[15]


  Amniotic Fluid: A Source of Regenerative Properties Top


Current research in regenerative medicine suggests that stem cells from amniotic fluid may be promising. In adult stem cells, epigenetic changes may be preserved, thus limiting their use for specific applications.[16] However, fetal stem cells are less differentiated when collected, and could be used more broadly. Furthermore, there are limited ethical concerns since the amniotic fluid is collected during amniocentesis and cesarean section.[17]

To further elucidate the therapeutic potential of amniotic fluid cells, signal transduction pathways triggered by human amniotic fluid stem cells (hAFSCs)-derived secretome in an I/R in vitro model were studied by Western blot analysis. In addition, the expression of miRNA within the exosomes of the conditioned medium was also studied. hAFSCs-derived secretome was observed to initiate pro-survival and anti-apoptotic mechanisms.[18] After microRNA analysis in the exosomes, it was found that 16 miRNAs were overexpressed and involved in the management of signaling pathways.[18] The pathways relating to I/R, including neurotrophin signaling, and those associated with neuroprotection and neuronal death, were of particular interest.[18] The evidence compiled proposes that hAFSCs-conditioned medium commences neuroprotective actions within in vitro ischemia models. These observed effects can be achieved through adjusting and initiated pro-survival processes, partially, due to the secreted miRNAs.


  The Role of Secretome and Exosomes in Neuroprotection Top


The amniotic fluid serves as a protective liquid that surrounds the fetus providing support and critical nutrients to aid in the development of the embryo.[19] The fluid consists of main water, cells, and other chemical elements.[20] The cells are primarily fetus-derived (respiratory, epithelial, urinary, and intestinal tract), as well as connective tissues and amniotic membranes. In addition, amniotic fluid possesses other cell subtypes such as amniotic, fibroblastic, and epithelioid, differing in prevalence depending on the age of gestation.[21] Amniotic fluid mesenchymal stem cells (AFMSCs) are of particular interest given their potential for therapeutic applications. AFMSCs have shown the ability to differentiated broadly toward chondrogenic, osteogenic, and adipogenic lineages, consequently presenting as a viable candidate for regenerative and therapeutic methods.[22]

However, there remains a concern on the ability of engrafted stem cells to develop into the specific cell type of the damaged area. The mechanism of action has been reported broadly,[23],[24],[25],[26] yet some of the exogenous cells that persist into the regenerated tissue do not completely explain the regenerative effects. Potentially, the insufficient integration may be due to a degree of differentiation that took place in vitro before transplant. Furthermore, it is worth noting that only some of the cell populations may undergo differentiation. This group of cells may elicit poor immune-activating responses but may recruit nearby progenitor cells to repair the injured tissue. Several studies support this theory, highlighting the protective ability of the conditioned medium in the regeneration of damaged areas where chronic inflammation persists.[27],[28],[29],[30]

Arising from previously described theories, efforts have been targeted towards stem cells secretome, and the effects it can have on stimulating regenerative pathways in damaged areas.[31],[32],[33] Within conditioned medium, there exists extracellular vesicles (EV) and other soluble factors. More recently, EV have been implicated in upregulating mesenchymal stem cells (MSCs) regenerative effects,[34],[35],[36],[37] however, this mechanism is not fully understood.

Exosomes are a subcategory of microvesicles, that have gained interests due to their ability to communicate from cell-to-cell, store biological information, serve as biomarkers, and their potential for regeneration and protection of the nervous system.[38],[39],[40] Exosomes are the result of fusing with the plasma membrane and releasing its contents outside of the cell.[38] The contents of an exosome usually consist of miDNA, DNA, proteins, carbohydrates, and lipids.[41],[42] Since exosomes are relatively simple in structure and small in size, they can cross the blood-brain barrier and present novel approaches for treatment delivery in cerebral injuries. Therefore, exosomes provide another therapeutic route besides cell transplanatation.[43]


  Mitochondria Direct Apoptosis Top


Deficits relating to I/R injuries can be traced back to the mitochondria. For example, when mitochondria are unable to produce a strong proton gradient, their ability to produce energy suffers and thus affect other organelles like the endoplasmic reticulum in calcium uptake. Furthermore, oxidative stress can result from changes in the mitochondria leading to a building up of reactive oxygen species.[44] As a result, irregular mitochondria often initiate pro-apoptotic factors in the cytosol or nucleus leading to apoptosis.[45]


  Human Amniotic Fluid Stem Cells-Secretome Initiates Pro-Survival and Pro-Apoptotic Pathways Top


Following MSCs or MSCs-CM administration, a decrease in apoptosis around the injury site, upregulation of pro-inflammatory factors, enhanced axonal growth, and neurogenesis and amelioration of neurological deficits have been shown [Figure 1].[30],[46],[47] Yet, it is the contents of the secretome that determine the therapeutic capacity.[48] In the CM, a myriad of regenerative properties and growth-stimulating factors exist, which originate from stem cells. Furthermore, proteomic studies demonstrate the presence of several cytokines and growth factors in CM.[49],[50] In fact, MSCs have an unparalleled ability to produce effective exosome-producing cells.[51]
Figure 1: A graphical abstract demonstrating the capacity of Human amniotic fluid stem cells.derived media to promote neuronal survival after exposed to ischemic conditions

Click here to view


Given such evidence, paired with the paracrine hypothesis, which poses that stem cells elicit a positive effect by stimulating resident cells to deliver bioactive molecules and EV, the use of secretome may be more advantageous than MSCs, especially in regard to safety. Recent studies have shown that the release of the secretome from MSCs could attenuate neurological impairments observed in several neurodegenerative diseases such as traumatic brain injury, Parkinson's disease, stroke, and Alzheimer's disease.[22],[52],[53],[54],[55] Conditioned media and secretome demonstrate the capacity to upregulate neurotrophins like BDNF, a vascular endothelial growth factor. Neurorestoration is initiated under the release of nerve growth factors that improve neuronal projections.[47],[56]

Several factors support the use of hAFSCs for safe and effective treatment in stroke including highly proliferative, low tumorgenicity, immunogenicity, and anti-inflammatory activity.[57] It was found that CM and more specifically, the exosomal component served an important role in fostering cell survival.[18] Increased survival was accompanied by suppressing cell-death pathways (p75/JNK) and upregulating pro-growth pathways (BDNF/TrkB).[18] In addition, pro-survival pathways PI3K/Akt and Erk5 were increased.[18]


  miRNA Contents Determines Therapeutic Capacity Top


Within exosomes are proteins, lipids, and regulatory RNAs that can be transferred and alter surrounding cell metabolism.[48] Interestingly, among MSC-derived exosome proteins, higher levels of mBDNF were observed. Previously, several studies demonstrated that exosomes contained various neuronal proteins, all capable of passing the blood-brain barrier.[58] Furthermore, it has been shown that high levels of mBDNF were found in both exosomal fractions and in soluble CM.[18]

In addition to previously discussed exosomal contents, numerous miRNAs have been found that can initiate neurorestoration. miRNAs that have been shown to have neuroprotective effects (miR-146a-5p, miR-154-5p, miR-22-3p, miR-23a-3p, miR-27a-3p, miR-29a-3p, and miR-31-5p) were also found in the hAFSC-derived exosomes studied. In particular, miR-146a was previously demonstrated to dampen inflammation[59],[60] and promote new formations of oligodendrocytes[61] within the injured perinatal brain. In promoting the growth of nervous tissue, miR-154 was observed in EV derived from astrocytes.[62] In addition, miR-154 has demonstrated to seek out DKK2, causing Wnt signaling activation and β-catenin upregulation,[63] both important pathways in synaptic maintenance and neuronal survival.[64] MiR-22-3p, 23a, and 27a all have roles in inhibiting apoptosis, thus providing neuroprotection.[65],[66],[67],[68],[69]

Recent studies suggest that miRNAs are dynamic in their response to ischemic conditions and are present in neuroprotection, such as TNF, Hippo, and PI3K.[70],[71],[72] From the miRNAs that afford neuroprotection, several genes were identified that are involved in modulating apoptosis and inflammation.[18]

In the HIF-1 pathway, a systemic deactivating mechanism can be seen from the experimentally based miRNAs and target genes. However, apoptosis, neurotrophins, and PI3K-Akt pathways, all expected to be mostly inactive, were observed taking part in upregulating or downregulating various processes such as apoptosis, proliferation, and inflammation. However, this response is undeviating with the pleiotropic and adaptive nature of miRNAs, since they can regulate the expression of many genes at the epigenetic level.[73] Despite the evidence, more investigation is needed to validate the role miRNAs have in regulating neurogenic pathways following ischemic injury. Furthermore, elucidating possible molecular mechanisms will aid in explaining the protective role miRNAs play in the central nervous system. Finally, it is certainly important to study how hAFSC-derived conditioned media behaves in vivo, as there are many other cells in the central nervous system besides neurons.

Acknowledgement

The figure was created using Adobe Photoshop.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Glushakova OY, Glushakov AV, Miller ER, Valadka AB, Hayes RL. Biomarkers for acute diagnosis and management of stroke in neurointensive care units. Brain Circ 2016;2:28-47.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Donkor ES. Stroke in the 21st Century: A snapshot of the burden, epidemiology, and quality of life. Stroke Res Treat 2018;2018:3238165.  Back to cited text no. 2
    
3.
Hui C, Tadi P, Patti L. Ischemic Stroke. Treasure Island, Florida: StatPearls Publishing; 2020.  Back to cited text no. 3
    
4.
Maestrini I, Ducroquet A, Moulin S, Leys D, Cordonnier C, Bordet R. Blood biomarkers in the early stage of cerebral ischemia. Rev Neurol (Paris) 2016;172:198-219.  Back to cited text no. 4
    
5.
Juan WS, Lin HW, Chen YH, Chen HY, Hung YC, Tai SH, et al. Optimal Percoll concentration facilitates flow cytometric analysis for annexin V/propidium iodine-stained ischemic brain tissues. Cytometry A 2012;81:400-8.  Back to cited text no. 5
    
6.
Li W, Yang S. Targeting oxidative stress for the treatment of ischemic stroke: Upstream and downstream therapeutic strategies. Brain Circ 2016;2:153-63.  Back to cited text no. 6
[PUBMED]  [Full text]  
7.
Lee JY, Castelli V, Bonsack B, García-Sánchez J, Kingsbury C, Nguyen H, et al. Eyeballing stroke: Blood flow alterations in the eye and visual impairments following transient middle cerebral artery occlusion in adult rats. Cell Transplant 2020;29:963689720905805.  Back to cited text no. 7
    
8.
Lee JY, Castelli V, Bonsack B, Coats AB, Navarro-Torres L, Garcia-Sanchez J, et al. A novel partial MHC Class II construct, DRmQ, inhibits central and peripheral inflammatory responses to promote neuroprotection in experimental stroke. Transl Stroke Res 2020;11:831-6.  Back to cited text no. 8
    
9.
L L, X W, Z Y. Ischemia-reperfusion Injury in the Brain: Mechanisms and Potential Therapeutic Strategies. Biochem Pharmacol (Los Angel) 2016;5.  Back to cited text no. 9
    
10.
Yu W, Liu L. Therapeutic window beyond cerebral ischemic reperfusion injury. In: Jiang W, Yu W, Qu Y, Shi Z, editors. Cerebral Ischemic Reperfusion Injuries (CIRI). Cham: Springer International Publishing; 2018. p. 245-59.  Back to cited text no. 10
    
11.
Tasca CI, Dal-Cim T, Cimarosti H. In vitro oxygen-glucose deprivation to study ischemic cell death. Methods Mol Biol 2015;1254:197-210.  Back to cited text no. 11
    
12.
Sommer CJ. Ischemic stroke: Experimental models and reality. Acta Neuropathol 2017;133:245-61.  Back to cited text no. 12
    
13.
Wang YJ, Peng QY, Deng SY, Chen CX, Wu L, Huang L, et al. Hemin protects against oxygen-glucose deprivation-induced apoptosis activation via neuroglobin in SH-SY5Y cells. Neurochem Res 2017;42:2208-17.  Back to cited text no. 13
    
14.
Niu G, Zhu D, Zhang X, Wang J, Zhao Y, Wang X. Role of hypoxia-inducible factors 1α (HIF1α) in SH-SY5Y cell autophagy induced by oxygen-glucose deprivation. Med Sci Monit 2018;24:2758-66.  Back to cited text no. 14
    
15.
Ryou MG, Mallet RT. An in vitro oxygen-glucose deprivation model for studying ischemia-reperfusion injury of neuronal cells. Methods Mol Biol 2018;1717:229-35.  Back to cited text no. 15
    
16.
Tuazon JP, Castelli V, Lee JY, Desideri GB, Stuppia L, Cimini AM, et al. Neural stem cells. Adv Exp Med Biol 2019;1201:79-91.  Back to cited text no. 16
    
17.
Loukogeorgakis SP, De Coppi P. Concise review: Amniotic fluid stem cells: The known, the unknown, and potential regenerative medicine applications. Stem Cells 2017;35:1663-73.  Back to cited text no. 17
    
18.
Castelli V, Antonucci I, d'Angelo M, Tessitore A, Zelli V, Benedetti E, et al. Neuroprotective effects of human amniotic fluid stem cells-derived secretome in an ischemia/reperfusion model. Stem Cells Transl Med 2020;10:251-66.  Back to cited text no. 18
    
19.
Roubelakis MG, Trohatou O, Anagnou NP. Amniotic fluid and amniotic membrane stem cells: Marker discovery. Stem Cells Int 2012;2012:107836.  Back to cited text no. 19
    
20.
Prasongchean W, Ferretti P. Autologous stem cells for personalised medicine. N Biotechnol 2012;29:641-50.  Back to cited text no. 20
    
21.
Loukogeorgakis SP, Maghsoudlou P, De Coppi P. Recent developments in therapies with stem cells from amniotic fluid and placenta. Fet Matern Med Rev 2013;24:148-68.  Back to cited text no. 21
    
22.
Tuazon JP, Castelli V, Borlongan CV. Drug-like delivery methods of stem cells as biologics for stroke. Expert Opin Drug Deliv 2019;16:823-33.  Back to cited text no. 22
    
23.
Abdelwahid E, Kalvelyte A, Stulpinas A, de Carvalho KA, Guarita-Souza LC, Foldes G. Stem cell death and survival in heart regeneration and repair. Apoptosis 2016;21:252-68.  Back to cited text no. 23
    
24.
Iismaa SE, Kaidonis X, Nicks AM, Bogush N, Kikuchi K, Naqvi N, et al. Comparative regenerative mechanisms across different mammalian tissues. NPJ Regen Med 2018;3:6.  Back to cited text no. 24
    
25.
Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J. Mesenchymal stem cells for regenerative medicine. Cells 2019;8:886.  Back to cited text no. 25
    
26.
Palladino A, Mavaro I, Pizzoleo C, De Felice E, Lucini C, de Girolamo P, et al. Induced pluripotent stem cells as vasculature forming entities. J Clin Med 2019;8:1782.  Back to cited text no. 26
    
27.
Chen ZY, Hu YY, Hu XF, Cheng LX. The conditioned medium of human mesenchymal stromal cells reduces irradiation-induced damage in cardiac fibroblast cells. J Radiat Res 2018;59:555-64.  Back to cited text no. 27
    
28.
El Moshy S, Radwan IA, Rady D, Abbass MM, El-Rashidy AA, Sadek KM, et al. Dental stem cell-derived secretome/conditioned medium: The future for regenerative therapeutic applications. Stem Cells Int 2020;2020:7593402.  Back to cited text no. 28
    
29.
Jha KA, Pentecost M, Lenin R, Klaic L, Elshaer SL, Gentry J, et al. Concentrated conditioned media from adipose tissue derived mesenchymal stem cells mitigates visual deficits and retinal inflammation following mild traumatic brain injury. Int J Mol Sci 2018;19:2016.  Back to cited text no. 29
    
30.
Sriramulu S, Banerjee A, Di Liddo R, Jothimani G, Gopinath M, Murugesan R, et al. Concise review on clinical applications of conditioned medium derived from human umbilical cord-mesenchymal stem cells (UC-MSCs). Int J Hematol Oncol Stem Cell Res 2018;12:230-4.  Back to cited text no. 30
    
31.
Drago D, Cossetti C, Iraci N, Gaude E, Musco G, Bachi A, et al. The stem cell secretome and its role in brain repair. Biochimie 2013;95:2271-85.  Back to cited text no. 31
    
32.
d'Angelo M, Cimini A, Castelli V. Insights into the effects of mesenchymal stem cell-derived secretome in Parkinson's disease. Int J Mol Sci 2020;21:5241.  Back to cited text no. 32
    
33.
Balbi C, Bollini S. Fetal and perinatal stem cells in cardiac regeneration: Moving forward to the paracrine era. Placenta 2017;59:96-106.  Back to cited text no. 33
    
34.
Campanella C, Caruso Bavisotto C, Logozzi M, Gammazza AM, Mizzoni D, Cappello F, et al. On the choice of the extracellular vesicles for therapeutic purposes. Int J Mol Sci 2019;20:236.  Back to cited text no. 34
    
35.
Park KS, Bandeira E, Shelke GV, Lässer C, Lötvall J. Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Stem Cell Res Ther 2019;10:288.  Back to cited text no. 35
    
36.
Taverna S, Pucci M, Alessandro R. Extracellular vesicles: Small bricks for tissue repair/regeneration. Ann Transl Med 2017;5:83.  Back to cited text no. 36
    
37.
Baek G, Choi H, Kim Y, Lee HC, Choi C. Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform. Stem Cells Transl Med 2019;8:880-6.  Back to cited text no. 37
    
38.
Kalani A, Tyagi N. Exosomes in neurological disease, neuroprotection, repair and therapeutics: Problems and perspectives. Neural Regen Res 2015;10:1565-7.  Back to cited text no. 38
[PUBMED]  [Full text]  
39.
Doyle LM, Wang MZ. Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis. Cells 2019;8:727.  Back to cited text no. 39
    
40.
Gurunathan S, Kang MH, Jeyaraj M, Qasim M, Kim JH. Review of the isolation, characterization, biological function, and multifarious therapeutic approaches of exosomes. Cells 2019;8:307.  Back to cited text no. 40
    
41.
Vyas N, Dhawan J. Exosomes: Mobile platforms for targeted and synergistic signaling across cell boundaries. Cell Mol Life Sci 2017;74:1567-76.  Back to cited text no. 41
    
42.
Schey KL, Luther JM, Rose KL. Proteomics characterization of exosome cargo. Methods 2015;87:75-82.  Back to cited text no. 42
    
43.
Aryani A, Denecke B. Exosomes as a nanodelivery system: A key to the future of neuromedicine? Mol Neurobiol 2016;53:818-34.  Back to cited text no. 43
    
44.
Liu F, Lu J, Manaenko A, Tang J, Hu Q. Mitochondria in ischemic stroke: New insight and implications. Aging Dis 2018;9:924-37.  Back to cited text no. 44
    
45.
Yang JL, Mukda S, Chen SD. Diverse roles of mitochondria in ischemic stroke. Redox Biol 2018;16:263-75.  Back to cited text no. 45
    
46.
Qu J, Zhang H. Roles of mesenchymal stem cells in spinal cord injury. Stem Cells Int 2017;2017:5251313.  Back to cited text no. 46
    
47.
Reza-Zaldivar EE, Hernández-Sapiéns MA, Minjarez B, Gutiérrez-Mercado YK, Márquez-Aguirre AL, Canales-Aguirre AA. Potential effects of MSC-derived exosomes in neuroplasticity in Alzheimer's disease. Front Cell Neurosci 2018;12:317.  Back to cited text no. 47
    
48.
Samanta S, Rajasingh S, Drosos N, Zhou Z, Dawn B, Rajasingh J. Exosomes: New molecular targets of diseases. Acta Pharmacol Sin 2018;39:501-13.  Back to cited text no. 48
    
49.
Pawitan JA. Prospect of stem cell conditioned medium in regenerative medicine. Biomed Res Int 2014;2014:965849.  Back to cited text no. 49
    
50.
Zagoura DS, Roubelakis MG, Bitsika V, Trohatou O, Pappa KI, Kapelouzou A, et al. Therapeutic potential of a distinct population of human amniotic fluid mesenchymal stem cells and their secreted molecules in mice with acute hepatic failure. Gut 2012;61:894-906.  Back to cited text no. 50
    
51.
Cosenza S, Toupet K, Maumus M, Luz-Crawford P, Blanc-Brude O, Jorgensen C, et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics 2018;8:1399-410.  Back to cited text no. 51
    
52.
Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gonçalves RM. Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning. Front Immunol 2018;9:2837.  Back to cited text no. 52
    
53.
Maacha S, Sidahmed H, Jacob S, Gentilcore G, Calzone R, Grivel JC, et al. Paracrine mechanisms of mesenchymal stromal cells in angiogenesis. Stem Cells Int 2020;2020:4356359.  Back to cited text no. 53
    
54.
Hasan A, Deeb G, Rahal R, Atwi K, Mondello S, Marei HE, et al. Mesenchymal stem cells in the treatment of traumatic brain injury. Front Neurol 2017;8:28.  Back to cited text no. 54
    
55.
Marques CR, Marote A, Mendes-Pinheiro B, Teixeira FG, Salgado AJ. Cell secretome based approaches in Parkinson's disease regenerative medicine. Expert Opin Biol Ther 2018;18:1235-45.  Back to cited text no. 55
    
56.
Harting MT, Srivastava AK, Zhaorigetu S, Bair H, Prabhakara KS, Furman NE, et al. Inflammation-stimulated mesenchymal stromal cell-derived extracellular vesicles attenuate inflammation: Stimulated EVs attenuate inflammation. Stem Cells 2018;36:79-90.  Back to cited text no. 56
    
57.
Elias M, Hoover J, Nguyen H, Reyes S, Lawton C, Borlongan CV. Stroke therapy: The potential of amniotic fluid-derived stem cells. Future Neurol 2015;10:321-6.  Back to cited text no. 57
    
58.
Kang X, Zuo Z, Hong W, Tang H, Geng W. Progress of Research on Exosomes in the Protection Against Ischemic Brain Injury. Front Neurosci 2019;13:1149.  Back to cited text no. 58
    
59.
Gaudet AD, Fonken LK, Watkins LR, Nelson RJ, Popovich PG. MicroRNAs: Roles in regulating neuroinflammation. Neuroscientist 2018;24:221-45.  Back to cited text no. 59
    
60.
Omran A, Peng J, Zhang C, Xiang QL, Xue J, Gan N, et al. Interleukin-1β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia 2012;53:1215-24.  Back to cited text no. 60
    
61.
Liu XS, Chopp M, Pan WL, Wang XL, Fan BY, Zhang Y, et al. MicroRNA-146a promotes oligodendrogenesis in stroke. Mol Neurobiol 2017;54:227-37.  Back to cited text no. 61
    
62.
Chaudhuri AD, Dastgheyb RM, Yoo SW, Trout A, Tallbot CC, Hao H, et al. TNFα and IL-1β modify the miRNA cargo of astrocyte shed extracellular vesicles to regulate neurotrophic signaling in neurons. Cell Death Dis 2018;9:363.  Back to cited text no. 62
    
63.
Sun LY, Bie ZD, Zhang CH, Li H, Li LD, Yang J. MiR-154 directly suppresses DKK2 to activate Wnt signaling pathway and enhance activation of cardiac fibroblasts. Cell Biol Int 2016;40:1271-9.  Back to cited text no. 63
    
64.
Chen CM, Orefice LL, Chiu SL, LeGates TA, Hatter S, Huganir RL, et al. Wnt5a is essential for hippocampal dendritic maintenance and spatial learning and memory in adult mice. Proc Natl Acad Sci U S A 2017;114:E619-28.  Back to cited text no. 64
    
65.
Jovicic A, Zaldivar Jolissaint JF, Moser R, Silva Santos Mde F, Luthi-Carter R. MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms. PLoS One 2013;8:e54222.  Back to cited text no. 65
    
66.
Sabirzhanov B, Zhao Z, Stoica BA, Loane DJ, Wu J, Borroto C, et al. Downregulation of miR-23a and miR-27a following experimental traumatic brain injury induces neuronal cell death through activation of proapoptotic Bcl-2 proteins. J Neurosci 2014;34:10055-71.  Back to cited text no. 66
    
67.
Chen Q, Xu J, Li L, Li H, Mao S, Zhang F, et al. MicroRNA-23a/b and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal apoptosis. Cell Death Dis 2014;5:e1132.  Back to cited text no. 67
    
68.
Cho KH, Xu B, Blenkiron C, Fraser M. Emerging Roles of miRNAs in Brain Development and Perinatal Brain Injury. Front Physiol 2019;10:227.  Back to cited text no. 68
    
69.
Ma J, Shui S, Han X, Guo D, Li T, Yan L. MicroRNA-22 attenuates neuronal cell apoptosis in a cell model of traumatic brain injury. Am J Transl Res 2016;8:1895-902.  Back to cited text no. 69
    
70.
Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience 2015;302:2-2.  Back to cited text no. 70
    
71.
Gong P, Zhang Z, Zou C, Tian Q, Chen X, Hong M, et al. Hippo/YAP signaling pathway mitigates blood-brain barrier disruption after cerebral ischemia/reperfusion injury. Behav Brain Res 2019;356:8-17.  Back to cited text no. 71
    
72.
Sánchez-Alegría K, Flores-León M, Avila-Muñoz E, Rodríguez-Corona N, Arias C. PI3K signaling in neurons: A central node for the control of multiple functions. Int J Mol Sci 2018;19:3725.  Back to cited text no. 72
    
73.
Chiu H, Alqadah A, Chang C. The role of microRNAs in regulating neuronal connectivity. Front Cell Neurosci 2014;7:283.  Back to cited text no. 73
    


    Figures

  [Figure 1]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Introduction: Up...
In vitro ...
Amniotic Fluid: ...
The Role of Secr...
Mitochondria Dir...
Human Amniotic F...
miRNA Contents D...
References
Article Figures

 Article Access Statistics
    Viewed17282    
    Printed30    
    Emailed0    
    PDF Downloaded2444    
    Comments [Add]    

Recommend this journal